Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May 13;9(7):ofac238.
doi: 10.1093/ofid/ofac238. eCollection 2022 Jul.

Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal

Affiliations
Case Reports

Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients Requiring Hospitalization: A Case Series Using Rifampin for Reversal

Dusten T Rose et al. Open Forum Infect Dis. .

Abstract

Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate coronavirus disease 2019. Drug-drug interactions between ritonavir and tacrolimus are underappreciated by nontransplant providers. We describe 2 solid organ transplant recipients prescribed nirmatrelvir/ritonavir for outpatient use who developed tacrolimus toxicity requiring hospitalization and were managed with rifampin for toxicity reversal.

Keywords: COVID-19; drug interactions; nirmatrelvir/ritonavir; tacrolimus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Time course of medication interactions and tacrolimus and serum creatinine trends. Serum trough tacrolimus and creatinine levels over hospital course for patient 1 (A) and patient 2 (B). The respective tables and graph detail the serum trough tacrolimus (dashed line) and creatinine (solid line) levels in relation to the dose and timing of nirmatrelvir/ritonavir (NIM-RTV), rifampin (RIF), and tacrolimus administration.

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention . COVID data tracker. 2022. https://covid.cdc.gov/covid-data-tracker/#trends_totalcases. Accessed 25 February 2022.
    1. Pfizer, Inc . Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. New York: Pfizer, Inc; 2021.
    1. Badri P, Dutta S, Coakley E, et al. Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir. Am J Transplant 2015; 15:1313–22. - PMC - PubMed
    1. van Maarseveen EM, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS 2012; 26:568–81. - PubMed
    1. Katzenmaier S, Markert C, Riedel K-D, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther 2011; 90:666–73. - PubMed

Publication types